DUBLIN--(BUSINESS WIRE)--The "Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2022" report has been added to ResearchAndMarkets.com's offering.
This "Amyloid precursor protein secretase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Amyloid precursor protein secretase inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Amyloid precursor protein secretase inhibitors: Overview
According to the beta-amyloid (Abeta) hypothesis, compounds that inhibit gamma-secretase, the pivotal enzyme that generates Abeta, are potential therapeutics for Alzheimer's disease (AD). Studies in both transgenic and non-transgenic animal models of AD have indicated that gamma-secretase inhibitors, administered by the oral route, are able to lower brain Abeta concentrations. Inhibition of gamma-secretase presents a direct target for lowering Aβ production in the brain as a therapy for Alzheimer's disease (AD).
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Amyloid precursor protein secretase inhibitors R&D. The therapies under development are focused on novel approaches for Amyloid precursor protein secretase inhibitors.
Amyloid precursor protein secretase inhibitors: Emerging Drugs Chapters
This segment of the Amyloid precursor protein secretase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Amyloid precursor protein secretase inhibitors: Emerging Drugs
Nirogacestat: SpringWorks Therapeutics
Nirogacestat is an oral, selective, small molecule, gamma secretase inhibitor (GSI) in Phase 3 clinical development for patients with desmoid tumors. Gamma secretase is a protease complex that cleaves, or divides, multiple transmembrane protein complexes, including Notch, which, when dysregulated, can play a role in activating pathways that contribute to desmoid tumor growth.
It is currently in Phase III stage of development for the treatment of Desmoid tumors and is being developed by SpringWorks Therapeutics.
AL101: Ayala Pharmaceuticals
AL101 is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of Adenoid cystic carcinoma (ACC). It is currently in Phase II stage of development for the treatment of Amyloid precursor protein secretase inhibitors and is being developed by Ayala Pharmaceuticals.
Amyloid precursor protein secretase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Amyloid precursor protein secretase inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players working on Amyloid precursor protein secretase inhibitors
There are approx. 5+ key companies which are developing the Amyloid precursor protein secretase inhibitors. The companies which have their Amyloid precursor protein secretase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, SpringWorks Therapeutics.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Amyloid precursor protein secretase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Amyloid precursor protein secretase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Amyloid precursor protein secretase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Amyloid precursor protein secretase inhibitors drugs.
Amyloid precursor protein secretase inhibitors Report Insights
- Amyloid precursor protein secretase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Amyloid precursor protein secretase inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Ayala Pharmaceuticals
- SpringWorks Therapeutics
- Pipeline Therapeutics
Key Products
- AL102
- AL101
- Nirogacestat
- PIPE-505
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/iioh
